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PMetabolic Effects of Weight
Loss on a Very-Low-Carbohydrate
Diet Compared With an Isocaloric
High-Carbohydrate Diet in Abdominally Obese Subjects
Jeannie Tay, BNUTRDIET (HONS),*† Grant D. Brinkworth, PHD,* Manny Noakes, PHD,*
Jennifer Keogh, MSC,* Peter M. Clifton, PHD*
Adelaide, Australia
Objectives This study was designed to compare the effects of an energy-reduced, isocaloric very-low-carbohydrate, high-fat
(VLCHF) diet and a high-carbohydrate, low-fat (HCLF) diet on weight loss and cardiovascular disease (CVD) risk
outcomes.
Background Despite the popularity of the VLCHF diet, no studies have compared the chronic effects of weight loss and meta-
bolic change to a conventional HCLF diet under isocaloric conditions.
Methods A total of 88 abdominally obese adults were randomly assigned to either an energy-restricted (6 to 7 MJ, 30%
deficit), planned isocaloric VLCHF or HCLF diet for 24 weeks in an outpatient clinical trial. Body weight, blood
pressure, fasting glucose, lipids, insulin, apolipoprotein B (apoB), and C-reactive protein (CRP) were measured at
weeks 0 and 24.
Results Weight loss was similar in both groups (VLCHF 11.9  6.3 kg, HCLF 10.1  5.7 kg; p  0.17). Blood pres-
sure, CRP, fasting glucose, and insulin reduced similarly with weight loss in both diets. The VLCHF diet produced
greater decreases in triacylglycerols (VLCHF 0.64  0.62 mmol/l, HCLF 0.35  0.49 mmol/l; p  0.01) and
increases in high-density lipoprotein cholesterol (HDL-C) (VLCHF 0.25  0.28 mmol/l, HCLF 0.08  0.17
mmol/l; p  0.002). Low-density lipoprotein cholesterol (LDL-C) decreased in the HCLF diet but remained un-
changed in the VLCHF diet (VLCHF 0.06  0.58 mmol/l, HCLF 0.46  0.71 mmol/l; p  0.001). However, a
high degree of individual variability for the LDL response in the VLCHF diet was observed, with 24% of individu-
als reporting an increase of at least 10%. The apoB levels remained unchanged in both diet groups.
Conclusions Under isocaloric conditions, VLCHF and HCLF diets result in similar weight loss. Overall, although both diets had
similar improvements for a number of metabolic risk markers, an HCLF diet had more favorable effects on the
blood lipid profile. This suggests that the potential long-term effects of the VLCHF diet for CVD risk remain a con-
cern and that blood lipid levels should be monitored. (Long-term health effects of high and low carbohydrate,
weight loss diets in obese subjects with the metabolic syndrome; http://www.anzctr.org.au; ACTR No.
12606000203550). (J Am Coll Cardiol 2008;51:59–67) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.050i
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current dietary recommendations for weight management
nd obesity treatment advocate the consumption of a
igh-carbohydrate, low-fat (HCLF), moderate energy-
estricted diet (1,2). However, there has been a resurgence
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ccepted July 30, 2007.n public interest in and use of a very-low-carbohydrate,
igh-fat (VLCHF) diet fueled by the epidemic of obesity
nd type 2 diabetes (3), and several recent randomized
ontrolled trials have demonstrated greater weight loss
ollowing the consumption of an VLCHF diet compared
ith a HCLF diet up to 6 months (4–7). However, these
tudies have been largely limited by high attrition rates, poor
ietary compliance, and limited dietary assessment. More
ecently, Gardner et al. (8) published a study that used more
ntensive interventional strategies to achieve better dietary
ompliance and higher subject retention and demonstrated
reater weight loss in overweight/obese women following an
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Metabolic Effects of VLCHF Diets January 1/8, 2008:59–67VLCHF diet after 12 months
compared with higher carbohy-
drate diets.
Despite potential weight-loss
advantages, concern remains that
chronic consumption of an
VLCHF diet, typically high in
saturated fat and cholesterol,
may have detrimental effects on
blood lipids and cardiovascular
disease (CVD) risk (9–12). Re-
cent studies have consistently
shown that compared with an
HCLF diet, an VLCHF diet
produces greater reductions in
triacylglycerols (TAG) and in-
creases in high-density lipopro-
tein cholesterol (HDL-C) and at
least comparable changes in
blood pressure and insulin resis-
tance, without detrimental effects
on low-density lipoprotein cho-
esterol (LDL-C) for periods up to 1 year (5–8,13). How-
ver, most of these studies have used a free-living, ad
ibitum approach that does not allow for the study of the
etabolic effects of such dietary patterns without associated
onfounding variables such as differences in energy intake.
or example, Gardner et al. (8) showed that weight-loss
ifferences between an VLCHF and HCLF diet influenced
he effect on CVD risk factor responses. Therefore, al-
hough ad libitum experimental designs are appropriate for
valuating effectiveness, there is still a lack of understanding
f the specific metabolic effects of VLCHF diets when
onsumed long term without the confounding effect of
ifferential weight loss. The aim of this study was to
ompare, under isocaloric and well-controlled diet condi-
ions, weight loss and the metabolic effects at 6 months of a
oderate energy-restricted VLCHF and HCLF diet in
bdominally obese subjects with elevated cardiovascular risk.
ethods
articipants. A total of 122 men and women, ages 18 to 65
ears, with abdominal obesity and the presence of at least 1
dditional metabolic syndrome risk factor (14) were re-
ruited by public advertisement. Exclusion criteria included
history of liver, cardiovascular, peripheral vascular, respi-
atory, or gastrointestinal disease; diabetes, or a malignancy.
ubjects provided written informed consent before partici-
ation, and all protocols and procedures were approved by
he Human Ethics Committee of the Commonwealth
cientific and Industrial Research Organisation.
Figure 1 shows participant flow. Baseline characteristics
etween diet groups were not different (Table 1). Overall,
6% of subjects had elevated TAG, 25% had reduced
Abbreviations
and Acronyms
apoB  apolipoprotein B
BMI  body mass index
CRP  C-reactive protein
CVD  cardiovascular
disease
HCLF  high-carbohydrate,
low-fat
HDL-C  high-density
lipoprotein cholesterol
HOMA-IR  homeostatic
model assessment-insulin
resistance
ITT  intention to treat
LDL-C  low-density
lipoprotein cholesterol
TAG  triacylglycerol
VLCHF  very-low-
carbohydrate, high-fatDL-C, 68% had elevated blood pressure, 42% had ele- eated fasting blood glucose, and 55% had at least 2 of these
isk factors and met the metabolic syndrome criteria (14).
here was no difference between diet groups in the presence
f these risk factors (p  0.29). Subjects who withdrew
efore the end of the study were similar to those who
ompleted the study for age, gender distribution, body mass
ndex (BMI), waist circumference, and other CVD risk
actors at baseline (p  0.22).
Of the 88 subjects who completed the study, 15 were
aking estrogens (hormone replacement therapy, n  11;
ral contraceptive pill, n  4), 27 were taking antihyper-
ensive medication, and 18 were taking lipid-lowering
edication. No subjects were taking hypoglycemic medication.
Medication distribution between the treatment groups
as not different. Throughout the study, 2 subjects in-
reased their hypertensive medication (1 in each diet group),
decreased their antihypertensive medication (n  4 for
LCHF and n  3 for HCLF), and 1 from the VLCHF
iet group decreased their lipid-lowering medication.
tudy design. In a parallel study design, subjects were
atched for age, gender, and BMI and randomly assigned
o either an VLCHF or HCLF diet for 24 weeks. At weeks
and 24, subjects attended the clinic after an overnight fast.
ody mass, height (baseline only), and blood pressure were
easured before a venous blood sample for the determina-
ion of glucose, insulin, lipids, apolipoprotein B (apoB),
-reactive protein (CRP), and plasma ketones. Ketones
ere also measured at week 8. During the study, subjects
ttended the clinic fortnightly for 8 weeks and monthly
hereafter for dietetic consultations and a weight check to
uantify time-course changes. No specific recommendations
ere given for physical activity, which was assessed using an
stablished questionnaire (15).
ietary interventions. The planned macronutrient profiles
f the dietary interventions were as follows: VLCHF diet
% of total energy as carbohydrate, 35% as protein, 61% as
otal fat (20% saturated fat); HCLF diet  46% of total
nergy as carbohydrate, 24% as protein, 30% as total fat
8% saturated fat). The diets were designed to be isoca-
oric, with a moderate energy restriction of 30% (6,000
J for women, 7,000 kJ for men). In the VLCHF diet,
arbohydrate intake was restricted to 20 g/day during the
rst 8 weeks of the study. Subjects were then given the
ption to increase carbohydrate intake to 40 g/day for
he remaining 16 weeks to facilitate dietary compliance.
ubjects in the HCLF diet were asked to restrict saturated
at intake to 10 g/day for the study duration. Key foods
epresentative of each diet’s macronutrient profile were
upplied fortnightly for the first 8 weeks to aid compliance.
hese foods were generally uncooked but preweighed to
rovide about 30% of total energy. In the subsequent 16
eeks, $40 food vouchers were provided to subjects monthly
o facilitate continued adherence.
Both dietary patterns were structured to include specific
ood quantities to ensure the correct macronutrient and
nergy requirements (Table 2). These foods were listed in a
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January 1/8, 2008:59–67 Metabolic Effects of VLCHF Dietsemiquantitative food record that subjects completed daily.
cales for weighing food were provided. At each clinic visit,
ubjects attended individual consultations with a qualified
ietitian during which detailed, individualized dietary ad-
ice, meal planning, and recipe information for each diet
as provided. Diet composition during the study was
ssessed using 3-day food records recorded every 2 weeks
nd analyzed using Foodworks Professional Edition version
software (Xyris Software 1998, Highgate Hill, Australia).
t baseline and week 24, dietary intake was assessed using
food frequency questionnaire (16).
nthropometric measurements and blood pressure. Body
ass was measured using calibrated electronic digital scales
Mercury AMZ14, Tokyo, Japan) to the nearest 0.05 kg,
ith subjects wearing light clothing and no footwear. Waist
ircumference was measured to the nearest millimeter using
standard nonstretching tape measure 3 cm above the iliac
rest. The average of 2 measures was recorded as the measured
Figure 1 CONSORT Diagram of the Study
HCLF  high-carbohydrate, low-fat diet; VLCHF  very-low-carbohydrate, high-fat diealue (cm). Resting blood pressure (mm Hg) was measured by pn automated sphygmomanometer (DYNAMAP 8100, Criti-
on, Tampa, Florida) with subjects in a seated position after
aving rested for a minimum of 5 min. Three readings were
aken, each separated by 2 min, with the average score
ecorded as the measured value.
iochemical analysis. Serum total cholesterol, HDL-C,
AG, total apoB (B100 and B48), CRP, and plasma
lucose were measured on a Roche Hitachi 902 auto-
nalyzer (Roche Diagnostics, Indianapolis, Indiana) using
tandard Roche enzymatic kits (Roche Diagnostics, Basel,
witzerland) compared to control sera. The LDL-C was
alculated according to the method described by Friedewald
t al. (17). Plasma insulin concentrations were determined
sing a commercial enzyme immunoassay kit (Mercodia
LISA, ALPCO Diagnostics, Uppsala, Sweden). The
omeostatic model assessment (HOMA) was used as a
urrogate measure of insulin resistance based on fasting
lucose and insulin concentrations, calculated as fastingt.lasma insulin concentration (mU/l)  fasting plasma
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Metabolic Effects of VLCHF Diets January 1/8, 2008:59–67lucose concentration (mmol/l)/22.5 (18). Plasma ketone
oncentrations were analyzed in duplicate on a Roche Hitachi
uto-analyzer using a RANBUT D-3-Hydroxybutyrate kit
RANDOX Laboratories Ltd., Antrim, United Kingdom).
tatistical analysis. All statistical analyses were performed
sing SPSS 14.0 for Windows (SPSS Inc., Chicago, Illi-
ois). Distribution was normal for all variables except
etones and insulin, which were normalized using logarith-
ic transformation before analysis with normal-scale values
resented. Differences in baseline characteristics between
ubject Characteristics at Baseline
Table 1 Subject Characteristics at Baseline
Characteristic VLCHF (n  45) HCLF (n  43)
n (men/women) 14/31 17/26
Age (yrs) 50.3 8.4 51.0 7.5
BMI (kg/m2) 33.9 4.3 33.5 4.1
Weight (kg) 94.4 15.5 95.2 12.6
Waist circumference (cm)
Men 109.1 10.0 109.8 7.2
Women 102.4 8.3 100.7 8.9
Systolic blood pressure (mm Hg) 133.5 14.5 136.1 12.6
Diastolic blood pressure (mm Hg) 73.6 11.6 77.8 10.1
Glucose (mmol/l) 5.7 0.6 5.7 0.8
Insulin (mU/l) 9.2 4.8 10.9 5.4
Cholesterol (mmol/l)
Total 5.4 0.9 5.4 0.8
HDL-C 1.4 0.3 1.3 0.4
LDL-C 3.2 0.9 3.3 0.7
Triacylglycerol (mmol/l)* 1.6 0.7 1.8 0.8
alues are mean  SD. To convert mmol/l to mg/dl, multiply value by 18 for glucose, 38.7 for
holesterol, and 88.6 for triacyglycerol. All baseline characteristics were not significantly different
etween diet groups (p 0.05) by Independent samples t test (continuous variables) and Pearson
hi-square (categoric variables). *Triacyglycerol represents triglycerides.
BMI  body mass index; HCLF  high-carbohydrate, low-fat diet; HDL-C  high-density lipopro-
ein cholesterol; VLCHF  very-low-carbohydrate, high-fat diet; LDL-C  low-density lipoprotein
holesterol.
Food Profile of Dietary Interventions
Table 2 Food Profile of Dietary Interventions
VLCHF, 6,000 kJ
125 ml full-fat milk
70 g full-fat cheddar cheese*
1 medium (50 to 55 g) egg
300 g (raw protein food) beef, chicken, fish
100 g (cooked weight) ham, tuna, beef, chicken, turkey*
At least 2.5 cups (green) vegetables
25 g (5 tsp) oil/butter
40 g raw unsalted mixed nuts*
2 standard alcoholic drinks/wk (optional)*Key food items provided in the first 8 weeks.
Abbreviations as in Table 1.roups and dietary data were compared using independent t
ests for continuous variables and Pearson chi-square test for
ategorical variables. Repeated-measures analysis of variance
ANOVA) with diet (i.e., VLCHF or HCLF) and gender
et as between-subjects factors and time (weeks 0 and 24) as
within-subject factor was used to assess the effects of
ietary intervention by comparing changes on the depen-
ant variables between the groups over time. Where there
as a significant main effect, post-hoc comparisons were
erformed as appropriate with Bonferroni’s adjustment for
ultiple comparisons to determine differences between
roup means. Intention-to-treat (ITT) analysis was per-
ormed using baseline weight or weight at last follow-up
isit carried forward for those who did not complete the
tudy to examine the change in weight from baseline to
eek 24. Pearson correlation analyses were conducted to
ssess the association of change between variables. Statisti-
al significance was set at p  0.05. All data are presented
s mean  SD unless otherwise stated.
esults
ietary analysis, compliance, and physical activity. The
eported dietary intakes over the 24-week period were
onsistent with the prescribed dietary interventions. Total
nergy intake was not different between the groups
VLCHF 6,714  764 kJ, HCLF 6,402  731 kJ; p 
.05), and the level of energy restriction significantly corre-
ated with the degree of weight loss (VLCHF r  0.31,
 0.04; HCLF r  0.30, p  0.05). Compared to
aseline, saturated fat intake increased by 6.8  16.7 g/day
n the VLCHF diet and decreased by 14.6  16.7 g/day in
he HCLF diet. From baseline, carbohydrate intake de-
reased by 141.4  77.6 g/day in the VLCHF diet and
HCLF, 6,000 kJ
300 ml skim milk
2 slices whole-grain bread (35 g/slice)
40 g high-fiber cereal, (e.g., Fibre Plus, All Bran)*
20 g reduced-fat cheese (2 times/wk)*
150 g raw meat, beef, chicken, pork, lamb (5 times/wk)*
300 g fruit
150 g fish (once/wk)
At least 2.5 cups vegetables
1 medium potato (3 times/wk)
100 g (dry wt.) pasta/rice (4 times/wk)*
100 g beans/lentils (2 times/wk)*
200 g diet yogurt (3 times/wk)
20 g raw unsalted nuts*
50 g tinned fish (3 times/wk)*
2 tsp polyunsaturated margarine
3 tsp vegetable oil (e.g., olive or canola oil)
2 standard alcoholic drinks/wk (optional)
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ion. Plasma ketone concentrations were not different be-
ween the groups at baseline. There was a significant time by
iet interaction for ketone bodies (p  0.001) such that
evels had increased more in the VLCHF diet compared
ith the HCLF diet by week 8 (Fig. 2). Ketone concentra-
ions declined in the VLCHF diet during the subsequent 16
eeks but remained 2-fold higher compared to the HCLF
iet at week 24, indicating compliance to a very-low-
arbohydrate intake on the VLCHF diet. At week 24,
arbohydrate intake negatively correlated with ketone con-
entration in the VLCHF diet (r  0.37, p  0.01), but
ot the HCLF diet (r  0.17, p  0.29). At baseline,
hysical activity levels were similar in both groups (p 
.55) and did not change in either group during the
ntervention (p  0.83).
eight loss. Over the 24 weeks, there were substantial
eductions in body weight in both groups (p  0.001), with
o significant difference between the diets, expressed either in
bsolute terms (VLCHF 11.9  6.3 kg, HCLF 10.1 
.7 kg; p  0.17) (Fig. 3) or as percentage weight loss
VLCHF 12.3  5.5%, HCLF 10.5  5.5%; p  0.14).
here was no effect of gender. The ITT with either baseline
alues carried forward or the last follow-up visit carried
orward for those who did not complete the study also showed
o difference in weight loss between the diets (p  0.23).
urthermore, there were no differences between the diets for
he proportion of subjects that exhibited 5% weight loss
VLCHF 41 of 45, HCLF 35 of 43; chi-square  1.76; p 
.18) and 10% weight loss (VLCHF 30 of 45, HCLF 23 of
3; chi-square  1.594; p  0.21). Subjects in the highest
Figure 2 Plasma Ketone Concentrations
Before and After Intervention
Ketone concentration at baseline and after 8 and 24 weeks of energy restric-
tion with an VLCHF diet (n  45) or an HCLF diet (n  43). *Significant time by
diet interaction between the groups (P0.001) by repeated measures analysis
of variance. †p  0.001, ‡p  0.01 significantly greater than HCLF by post-
hoc comparisons at each time point with Bonferonni adjustment for 3 compari-
sons. Abbreviations as in Figure 1.dertile of carbohydrate intake at baseline (214 g/day) did
ot experience greater weight loss on the VLCHF diet
ompared with the HCLF diet (p  0.10, time by diet
nteraction). At week 24, weight loss correlated with ketone
oncentration in the VLCHF diet (r  0.45, p  0.002),
ut not in the HCLF diet (r  0.20, p  0.20).
ipids and apoB. There was a significant effect of diet on
otal and LDL-C (p  0.005, time by diet interaction)
hereby these parameters decreased in the HCLF diet (p
.001) but did not change in the VLCHF diet (p  0.52)
Table 3). Subjects in the highest tertile according to
aseline LDL-C (4.11 mmol/l, n  29) showed larger
DL-C reductions in the HCLF diet compared with the
LCHF diet (VLCHF 0.23  0.54 mmol/l, HCLF
0.76  0.72 mmol/l; p  0.03). A greater proportion of
ubjects on the VLCHF diet compared with the HCLF diet
xperienced an increase in LDL-C of at least 5% (VLCHF
6% [16 of 45]; HCLF 12% [5 of 42]; chi-square  6.64,
 0.01) and 10% (VLCHF 24% [11 of 45]; HCLF 10%
4 of 42]; chi-square  3.39, p  0.06). The LDL
ecreased in 58% (26 of 45) and 79% (33 of 42) of subjects
n the VLCHF and HCLF diets, respectively (chi-square 
.30, p  0.04). For LDL-C, a significant effect of gender
as also observed (p  0.04 time  diet  gender
nteraction), such that LDL-C decreased in both genders
n the HCLF diet (men 0.57  0.97 mmol/l, women
0.39  0.51 mmol/l; p  0.57) but increased in men and
ecreased in women on the VLCHF diet (men 0.21  0.62
mol/l, women 0.18  0.52 mmol/l; p  0.03). Com-
ared to baseline, apoB concentrations were reduced by 1%
n the VLCHF diet and 4.9% in the HCLF diet, but this
id not reach statistical significance, and there was no
Figure 3 Body Weight Before and After Intervention
Body weight at baseline and after 24 weeks of energy restriction consumption
of an VLCHF diet (n  45) or an HCLF diet (n  43). Both diets significantly
different (p  0.001) from baseline (time effect). There was no significant time
by diet interaction (p  0.05) over 24 weeks by repeated-measures analysis of
variance. Abbreviations as in Figure 1.ifference between the diets (p  0.52) (Table 3).
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Metabolic Effects of VLCHF Diets January 1/8, 2008:59–67High-density lipoprotein increased more in the VLCHF
iet than in the HCLF diet (VLCHF 18% vs. HCLF 6%,
 0.002 time  diet interaction). There was no effect of
ender. For subjects in the lowest tertile of baseline HDL-C
1.23 mmol/l; n  29), HDL-C increased more in the
LCHF diet compared with the HCLF diet (VLCHF
.41  0.20 mmol/l, HCLF 0.11  0.09 mmol/l; p 
.001). Similarly, for subjects in the highest tertile of
aseline HDL-C (1.49 mmol/l; n  29), there was a
ignificant time by diet interaction (p  0.003), with an
ncrease in the VLCHF diet (0.25  0.24 mmol/l, p 
.001), but no change in the HCLF diet (0.05  0.24
mol/l, p  0.52).
Diet composition had a significant effect on TAG, with a
-fold greater reduction in the VLCHF diet compared with
he HCLF diet (p  0.01 time  diet effect). No effect of
ender was observed. For subjects in the highest tertile of
aseline TAG (1.83 mmol/l; n  29), those in the
LCHF diet displayed greater reductions in TAG com-
ared with the HCLF diet (VLCHF1.31 0.61 mmol/l,
CLF 0.34  0.67 mmol/l; p  0.001). A significant
ffect of diet composition on TAG according to HOMA
tatus was also observed whereby subjects in the highest
ertile according to baseline HOMA scores (2.72, n 29)
orresponding to those with the highest degree of insulin
esistance showed a larger reduction in the VLCHF diet
ompared with the HCLF diet (VLCHF 0.89  0.53
mol/l, HCLF 0.25  0.67 mmol/l, p  0.009).
lood pressure, glucose, insulin, and CRP. Blood pres-
ure, fasting glucose, insulin, and HOMA were all reduced
ith weight loss, with no significant effect of diet compo-
erum Lipids and Apo-B Concentrations Before and After the 24-W
Table 3 Serum Lipids and Apo-B Concentrations Before and Aft
VLCHF
Week 0 Week 24
Total cholesterol (mmol/l)* 5.39 0.93 5.37 1.19
LDL-C (mmol/l)* 3.24 0.93 3.19 0.94
HDL-C (mmol/l)* 1.42 0.28 1.67 0.36
TAG (mmol/l)* 1.60 0.69 0.96 0.35
ApoB (g/l) 0.98 0.22 0.96 0.25
alues are mean  SD. *Significant time  diet interaction (p  0.05) by repeated measures ana
omparisons, with Bonferonni adjustment for 2 comparisons.
ApoB  apolipoprotein B; TAG  triacyglycerol; other abbreviations as in Table 1.
lood Pressure, Glucose, Insulin, HOMA-IR, and CRP Concentration
Table 4 Blood Pressure, Glucose, Insulin, HOMA-IR, and CRP C
VLCHF
Week 0 Week 24
Systolic blood pressure (mm Hg) 133.1 14.4 120.8 11.5
Diastolic blood pressure (mm Hg) 73.6 11.6 69.0 11.7
Glucose (mmol/l) 5.67 0.57 5.49 0.48
Insulin (mU/l) 9.15 4.82 6.17 3.48
HOMA-IR 2.35 1.42 1.54 1.32
CRP (mg/l) 3.21 2.00 2.01 1.58alues are mean  SD. No significant time  diet interaction (p  0.05) for these parameters. *p  0.0
CRP  C-reactive protein; HOMA-IR  homeostatic model assessment insulin resistance; other abbrevition (p 0.57) (Table 4). At baseline, CRP was positively
orrelated with BMI in both diet groups (VLCHF r 0.33,
 0.04; HCLF r  0.51, p  0.003). Subjects with CRP
evels10 mg/l (VLCHF 7, HCLF 11) were excluded
rom analysis. C-reactive protein decreased significantly
ith weight loss in both groups (p 0.001), independent of
iet composition (p  0.64) (Table 4). The change in CRP
egatively correlated with percentage weight loss (r 
0.29, p  0.02). Similarly, a subanalysis of subjects with
levated CVD risk indicated by CRP 3 mg/l at baseline
n  33) showed a reduction in CRP with weight loss, with
o significant diet effect (p  0.38).
iscussion
he results of this study demonstrate that under isocaloric
onditions, an energy-restricted VLCHF diet results in
imilar weight loss, as well as reductions in blood pressure,
lasma glucose, insulin, and CRP concentrations compared
ith an HCLF diet. However, differential diet effects on
ipid profile were observed, and a large individual variability
n LDL-C response was associated with the VLCHF diet,
hich may limit the generalizability of this diet.
A high level of dietary compliance was achieved, as
videnced by both the dietary data and objectively by the
lasma ketones response observed. Ketone levels remained
ow in the HCLF diet but were elevated in the VLCHF
iet, with an inverse correlation between carbohydrate
ntake and ketone concentrations.
The current study differs from previous investigations
hat have compared the chronic effects of VLCHF and
ietary Intervention
e 24-Week Dietary Intervention
HCLF
hange Week 0 Week 24 Change
 0.81 5.39 0.77 4.85 0.84 0.54 0.79†
 0.58 3.26 0.72 2.80 0.74 0.46 0.71†
 0.28† 1.33 0.35 1.41 0.30 0.08 0.17†
 0.62† 1.78 0.79 1.43 0.96 0.35 0.49†
 0.18 1.00 0.19 0.95 0.26 0.05 0.19
variance. †p  0.001: significantly different from baseline (time effect) by post-hoc within group
fore and After the 24-Week Dietary Intervention
ntrations Before and After the 24-Week Dietary Intervention
HCLF
Change Week 0 Week 24 Change
2.3 14.1 136.1 12.6 125.2 15.8 10.8 13.2
.58 9.78* 77.8 10.1 72.3 9.01 5.50 8.60*
.18 0.40* 5.60 0.55 5.38 0.49 0.21 0.40*
.99 3.31* 10.9 5.40 7.45 3.44 3.43 4.63*
.81 1.03* 2.81 1.62 1.84 1.05 0.97 1.34*
.11 1.46* 3.62 2.66 2.35 1.92 1.27 1.95*eek D
er th
C
0.02
0.06
0.25
0.64
0.02
lysis ofs Be
once
1
4
0
2
0
11: significantly different from baseline (time effect).
iations as in Table 1.
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January 1/8, 2008:59–67 Metabolic Effects of VLCHF DietsCLF diets when consumed ad libitum, as our purpose was
o specifically assess the metabolic effects of these diets when
atched in energy intake. After 6 months, we did not
bserve a metabolic weight loss advantage with the VLCHF
iet, although numerically there was a greater weight loss
ith the VLCHF diet. In contrast, we previously showed
19) over a shorter period (12 weeks) that an energy-
estricted VLCHF produced greater weight loss compared
ith an isocaloric HCLF diet (9.2% vs. 7.0%). Collectively,
his suggests that under energy-controlled conditions, the
LCHF diet may confer a small, transient weight-loss
dvantage that does not persist over the longer term.
educed thermodynamic efficiency associated with VLCHF
iets has been proposed to explain this metabolic advantage,
lthough the supporting evidence is scant (20,21). Measure-
ent of resting energy expenditure and the thermic effect of
eals in future isocaloric studies may provide some expla-
ation. Although proponents of VLCHF diets suggest (22)
hat ketosis from severe carbohydrate restriction is essential
o maximize weight loss, previous studies have shown no
ssociation between ketonuria and weight loss (4,5). How-
ver, these studies were limited by high withdrawal rates and
oor dietary adherence. In the present study, although we
bserved a positive correlation between ketone concentra-
ion and weight loss and markedly elevated ketone levels in
he VLCHF diet, weight loss in both groups remained
imilar at 24 weeks. This suggests that ketosis may be a
eflection of dietary compliance rather than causation.
In contrast to our findings, recent long-term ad libitum
tudies have demonstrated greater weight loss following
onsumption of the VLCHF diet compared with the
CLF diet after 6 months (4–7,13) and 1 year (8). This
ould be related to greater satiety associated with a higher
rotein intake (23), the severely limited food choices (24),
he simplicity of the carbohydrate avoidance strategy, or a
ombination of these. Conversely, the larger variety of foods
ermitted in ad libitum HCLF diets may have promoted a
reater potential for small but cumulative overconsumption
f more food items. A greater food variety could also result
n more complex meals, with a potential for the underre-
orting of some food items in dietary records. This may
rovide an explanation for the observations of previous
tudies that report greater weight loss following the con-
umption of the VLCHF diet compared with the HCLF
iet, despite reported total energy intake being lower or
omparable in the VLCHF diet (4,8).
Consistent with other recent studies (5–7,13,19), the
LCHF diet produced greater reductions in TAG and
ncreases in HDL-C than the HCLF diet. This suggests
hat the VLCHF diet as a weight loss strategy may confer
he greatest clinical benefits in patients who present with
ypertriglyceridemia, low HDL levels, abdominal adiposity,
nd insulin resistance (14). In contrast, greater reductions in
otal cholesterol and LDL-C were observed with the
CLF diet, although levels in the VLCHF diet remained
nchanged. This is consistent with a number of previous dtudies (4,5,7,25,26). It has been suggested (27) that apoB,
hich represents the actual number of atherogenic lipopro-
ein particles, may be a more reliable indicator of CVD risk.
lthough there was some evidence for a reduction com-
ared with baseline, apoB levels did not change significantly
y week 24 in either diet group, suggesting that athero-
enicity did not change despite a high or low saturated fat
ntake and the absence of an expected reduction in LDL-C
ith weight loss in the VLCHF diet (28). A meta-analysis
howed that apoB levels were not affected by the replace-
ent of dietary carbohydrate with saturated fat (29).
It is possible that the anticipated increase in LDL-C
econdary to a high saturated fat intake in the VLCHF diet
ay have been mitigated by the effects of energy restriction
nd weight loss (28). However, there was no correlation
etween the change in LDL-C and the change in saturated
at intake or weight loss, suggesting the influence of other
actors. A high saturated fat intake in the context of a
arbohydrate-restricted diet has been shown to increase
arger rather than smaller atherogenic LDL particles
30,31). This evidence suggests that the LDL-C elevating
ffects of saturated fat may be dependent on specific dietary
onditions and that the VLCHF diet may differentially alter
ipoprotein metabolism. On the basis of these findings, the
ffect of replacing saturated fat with cis-unsaturated fat in
he context of an VLCHF diet is worthy of investigation.
Although no large increases in mean LDL-C concentra-
ion occurred in the VLCHF diet, it is important to note
hat substantial variability in LDL response was observed,
ith approximately one-half of the group showing a de-
rease and vice versa. This high individual variability has
een previously reported in smaller studies (32). Therefore,
t is possible that some individuals may have a more sensitive
ipoprotein response to increases in saturated fat intake (33),
ut this has remained largely unexplained. In the present
tudy, we showed a differential gender response for LDL-C
ith consumption of the VLCHF diet such that the mean
hange decreased in women and increased in men. Other
tudies in humans (34,35) have also observed gender differ-
nce in lipoprotein responses to diets. Our results suggest
hat LDL-C in men could be of some concern because of
he strong level of evidence that lipid lowering reduces the
isk of coronary heart disease (36). The exact reason for the
ender differences and high variability in the responsiveness
f LDL-C to the VLCHF diet cannot be determined from
he present data, but interactions between diet and genetic
raits could play a role (37). Hence, monitoring lipid level
ay be prudent in patients adopting the VLCHF diet.
onclusions
fter 6 months, isocaloric energy-restricted VLCHF and
CLF diets produced similar weight loss and substantial
eductions in a number of CVD risk markers. Neither diet
isplayed adverse atherogenic effects, suggesting that diverse
ietary patterns, including VLCHF diets, may be tailored to
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Metabolic Effects of VLCHF Diets January 1/8, 2008:59–67n individual’s metabolic profile and dietary preference for
eight management. The HCLF diet had more favorable
ffects on LDL-C, whereas the VLCHF diet had more
avorable effects on TG and HDL-C, suggesting that the
atter approach may have relevance for the management of
he metabolic syndrome. However, individual metabolic
esponsiveness remains an important consideration. Further
esearch is warranted to determine the impact of both
ietary patterns on longer term cardiovascular and other
ealth outcomes and in individuals with advanced metabolic
isease, such as type 2 diabetes.
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